End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- AUD | -.--% | -.--% | -.--% |
Apr. 19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
Apr. 15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Sales 2024 * | 1.6M 1.05M | Sales 2025 * | 6.4M 4.2M | Capitalization | 48.77M 32M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.25M | Net income 2025 * | -5M -3.28M | EV / Sales 2024 * | 26 x |
Net cash position 2024 * | 7.1M 4.66M | Net cash position 2025 * | 9.4M 6.17M | EV / Sales 2025 * | 6.15 x |
P/E ratio 2024 * |
-5.65
x | P/E ratio 2025 * |
-11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.68% |
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 16-11-06 |
Mark Edwards
DFI | Director of Finance/CFO | - | 22-11-01 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | Nov. 28 | |
Philip Powell
BRD | Director/Board Member | 65 | 19-06-17 |
Geoff Cumming
BRD | Director/Board Member | - | 20-07-27 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.20% | 42.75B | |
+47.81% | 41.61B | |
+12.46% | 41.34B | |
-12.36% | 26.59B | |
+8.71% | 25.49B | |
-23.55% | 18.12B | |
+30.90% | 12.24B | |
-1.85% | 11.76B | |
+8.47% | 11B |
- Stock Market
- Equities
- IIQ Stock
- BD1 Stock